Amgen
Search results
Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Gilead Sciences, Inc. (/ ˈ ɡ ɪ l i ə d /) is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Jun 20, 2024 · Foster City, Calif. – June 20, 2024 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in ...
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Jun 20, 2024 · Gilead Sciences said on Thursday a late-stage study showed its long-acting injectable drug was more effective in preventing HIV infection in women compared to its existing daily pill Truvada ...
Jun 20, 2024 · Gilead Sciences Inc.’s stock GILD jumped 4.5% early Thursday after the company said its experimental twice-yearly injection for HIV prevention was found 100% effective in a late-stage trial.
2 days ago · Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Feb 15, 2024 · Gilead Sciences said on Thursday enrollments to test its cancer drug, magrolimab, on solid tumors had been paused globally, a week after the U.S. regulator put some studies on hold following ...
4 days ago · Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C.
